Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors

Summary

Clinical study of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity (ies) of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid tumors.

Timeline

Start

2012-12

Primary completion

2014-11

Completion

2014-12

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision not related to patient safety”

Drugs

Indications